To read the full story, subscribe or sign in.

Candid, Epimab ink $1B T-cell engager deal in autoimmune disease

Dec. 17, 2024

Candid Therapeutics Inc. and Epimab Biotherapeutics Inc. have entered a $1 billion research collaboration to discover and develop novel T-cell engager candidates for autoimmune indications.

BioWorld BioWorld Asia Deals and M&A Inflammatory Musculoskeletal Cell therapy Asia-Pacific China

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Upgrade your daily dose of biopharma and medtech news

Candid, Epimab ink $1B T-cell engager deal in autoimmune disease